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Aims: Recommendations for metformin use are dependent on eGFR category: eGFR >45 ml/min/
1.73 m2 – “ﬁrst-line agent”; eGFR 30–44 – “use with caution”; eGFR<30 – “do not use”. Misclassiﬁcation
of metformin eligibility by creatinine-based MDRD GFR estimates (eGFRcr) may contribute to its misuse.
We investigated the impact of cystatin c estimates of GFR (eGFRcys) on metformin eligibility.
Methods: In a consecutive cohort of 550 Veterans with diabetes, metformin use and eligibility were as-
sessed by eGFR category, using eGFRcr and eGFRcys. Discrepancy in eligibility was deﬁned as cases where
eGFRcr and eGFRcys categories (<30, 30–44, 45–60, and >60 ml/min/1.73 m2) differed with an absolute
difference in eGFR of >5 ml/min/1.73 m2. We modeled predictors of metformin use and eGFR category
discrepancy with multivariable relative risk regression and multinomial logistic regression.
Results: Subjects were 95% male, median age 68, and racially diverse (45% White, 22% Black, 11% Asian,
22% unknown). Metformin use decreased with severity of eGFRcr category, from 63% in eGFRcr >60 to
3% in eGFRcr <30. eGFRcys reclassiﬁed 20% of Veterans into different eGFR categories. Factors associ-
ated with a more severe eGFRcys category compared to eGFRcr were older age (aOR = 2.21 per decade,
1.44–1.82), higher BMI (aOR = 1.04 per kg/m2, 1.01–1.08) and albuminuria >30mg/g (aOR = 1.81, 1.20–2.73).
Conclusions: Metformin use is low among Veterans with CKD. eGFRcys may serve as a conﬁrmatory es-
timate of kidney function to allow safe use of metformin among patients with CKD, particularly among
older individuals and those with albuminuria.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Goals of Healthy People 2020 include developing strategies for
safe and effective glycemic control [1]. One key strategy to attain
this goal is to promote greater use of metformin. Compared to other
oral hypoglycemic agents, metformin is associated with decreased
risk of cardiovascular events, slower progression of chronic kidney
disease (CKD) and lower death rates [2,3]. Also, metformin does not
induce hypoglycemia, a common and potentially very serious adverse
side effect of insulin secretagogues, such as sulfonylureas [4].
Because metformin is renally cleared, individuals with severely
reduced kidney functionwho usemetforminmay be at risk of lactic
acidosis [4,5]. Since its introduction to the US market, metformin
has thus been labeled with a black box warning contraindicating
its use amongmenwith a serumcreatinine of ≥1.5mg/dL andwomen
with a serum creatinine of ≥1.4 mg/dL. As the beneﬁts of metformin
have become more widely appreciated, there has been an ongoing
debate as to whether these serum creatinine thresholds are too re-
strictive andwhether estimated glomerular ﬁltration rate (eGFR) is
a more accurate estimation of kidney function and thus metformin
eligibility [6]. The United KingdomNational Institute for Health and
Clinical Excellence (NICE) andKidneyDisease ImprovingGlobal Out-
comes speciﬁcally recommenduse ofmetformin for individualswith
an estimated glomerular ﬁltration rate (eGFR) of ≥45 ml/min/
1.73 m2, review and cautious use of lower doses of metformin for
individuals with an eGFR of 30–44 ml/min/1.73 m2, and not to use
metformin for individualswith an eGFR of <30ml/min/1.73 m2 [7,8].
In a 2012 joint position statement, the American Diabetes Associ-
ation and European Association for the Study of Diabetes concluded
that these guidelines appeared very reasonable [9].
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However, metformin is underused among individuals with di-
abetes and CKD [10]. This is likelymultifactorial, including conﬂicting
messages between the FDA and the aforementioned professional
societies [10–12]. Clinician concerns aboutmisclassiﬁcation of kidney
function by eGFRcr may also be contributing. The aforementioned
recommendations are based upon creatinine estimates of kidney
function (eGFRcr), which are inﬂuenced by age, gender, ethnicity,
andmusclemass. Importantly, these equations do not includemuscle
mass per se, but use age, gender, and ethnicity to estimate it. Use
of creatinine-based estimates of kidney function may thus lead to
biases in GFR estimation across and within individuals [13].
Cystatin C estimates of kidney function (eGFRcys) appear to be
more accurate than eGFRcr in older, unselected adults, and they have
been more strongly associated with health outcomes across nu-
merous research cohorts [14]. eGFRcys is independent of muscle
mass [15]. National and international CKD guidelines now recom-
mend the use of cystatin C to conﬁrm eGFR among individuals for
whom eGFRcr may be unreliable [16], such as in older, frail adults
among whom creatinine generation due to loss of muscle mass may
decrease in parallel with GFR decline, effectively masking the actual
loss of GFR [17]. This is also of concern for diabetic adults, in whom
skeletal muscle mass is also reduced relative to total body mass
[18,19].
Our objectives in this study were: 1) to examine independent
predictors of metformin use; 2) to compare categorization of kidney
function based upon eGFRcys versus MDRD eGFRcr to determine
metformin eligibility among adults with diabetes; 3) to identify char-
acteristics associated with different eGFR categories by cystatin C
and creatinine.
Subjects, materials and methods
Study design and study participants
This was a cross-sectional study using data from a cohort of adult
Veterans with diabetes who were receiving primary care at the San
Francisco Veterans Administration Medical Center (SFVAMC). Vet-
erans were eligible for this study if they were included in the local
Medical Practice Performance Measures Dashboard, a local diabe-
tes registry designed to improve the quality of diabetes care delivered
to adult Veterans, and if they received their medications from the
SFVAMC pharmacy. The ﬁrst 550 patients who met these criteria
were included in this study. The study protocol was approved by
the Committee of Human Research at the SFVAMC and University
of California, San Francisco.
Data collection
Participant demographic information (age, gender, race/ethnicity),
body-mass index (BMI), co-morbid conditions from the problem
list (hypertension, cardiovascular disease, congestive heart failure),
diabetes medication use (metformin, sulfonylurea, insulin,
thiazolidinedione), and laboratory data (glycosylated hemoglobin,
urinary albumin-to-creatinine ratio, serum creatinine, MDRD eGFRcr)
were ascertained by chart review between November 2013 and
March 2014. Only data updated in the prior three months were ab-
stracted. Serum creatinine andMDRD eGFRmeasures were obtained
for clinical purposes andwere available to clinicians. CKD-EPI eGFRcr
and cystatin C were obtained only for research purposes and were
not available to clinicians. The creatinine assay was IDMS standard-
ized. Cystatin C measures were performed on a Beckman Synchron
DX600 analyzer with reagents produced by Gentian (Norway) and
distributed by Beckman. Intra-assay coeﬃcients of variation for
cystatin C, estimatingwithin-run precision, ranged from 0.80 to 1.71%
withmean serum concentrations between 0.96 and 2.95mg/L. Inter-
assay coeﬃcients of variation for cystatin C, estimating day-to-
day precision, ranged from 2.76 to 3.37% with mean serum
concentrations between 1.01 and 3.93 mg/L.
Deﬁnitions
Metformin eligibility by clinical eGFR category was deﬁned using
the most recent recommendations [6,9]: ﬁrst line agent if eGFR
>60ml/min1/.73 m2; ﬁrst line agent if eGFR 45–60ml/min/1.73 m2;
use with caution if eGFR 30–44 ml/min/1.73 m2; do not use if eGFR
<30 ml/min/1.73 m2. Discrepancy between eGFRcys and MDRD
eGFRcr was deﬁned as cases where clinical eGFR categories dif-
fered by GFR estimate and the eGFR values were at least 5 ml/min/
1.73 m2 apart.
Covariates
Candidate covariates included demographic characteristics (age,
gender, race/ethnicity), co-morbid conditions (hypertension, hy-
perlipidemia, cardiovascular disease, congestive heart failure), BMI,
treatment of diabetes using glycosylated hemoglobin and urine
albumin-to-creatinine ratio (ACR). We examined the relationship
of continuous parameters including age, BMI, glycosylated hemo-
globin and ACR using smoothing splines to determine whether
associations with outcomes were linear [20]. In the ﬁnal models,
we dichotomized glycosylated hemoglobin (≥7%, ≥5.30 mmol/
mol) and ACR (>30mg/g). Multiple imputationwith theMarkov chain
Monte Carlo method was used to impute missing covariates, with
10 imputations to yield ~95% relative eﬃciency [21].
Statistical methods
Participant characteristics and diabetic medication use were com-
pared by eGFR category using the Kruskal–Wallis test for continuous
parameters and χ2 tests for categorical parameters. Multivariable
relative risk regressionwith a robust variance estimator and a Poisson
working model was used to identify predictors of metformin use
[22]. We used stepwise backward selection with a signiﬁcance level
of α = 0.05 to remove candidate covariates that were not associ-
ated with the outcome. In addition to the candidate covariates listed
above, either eGFRcr or serum creatinine was included in themodels
for metformin use. Reclassiﬁcation of metformin eligibility by eGFR
estimating equation was also performed across the clinical eGFR
categories. We calculated the number-needed-to-screen (NNS)
by cystatin C to identify a patient with an eGFR of <30 ml/min/
1.73 m2, as this person would not be eligible for metformin.
Multinomial logistic regression was used to identify factors asso-
ciated with bidirectional discrepancy between eGFRcys and eGFRcr
categories using agreement between methods (“same category”) as
the reference group. Sensitivity analyses were performed using
eGFRcr deﬁned by CKD-EPIcr [23] to broaden generalizability of study
results to institutions that use CKD-EPIcr estimates of GFR for clin-
ical purposes. All analyses were conducted using the SAS system,
version 9.3 (SAS Institute, Inc., Cary, NC).
Results
Characteristics of the study population
Overall, the 550 cohort subjects were 95%male, of diverse racial/
ethnic backgrounds (45% White, 22% Black, 11% Asian, 22%
unknown), and had a median age of 68 years. The median MDRD
eGFRcr, CKD-EPI eGFRcr and eGFRcyswere 73ml/min/1.73m2, 69ml/
min/1.73 m2, and 59 ml/min/1.73 m2, respectively. Characteristics
included in our analysis are summarized in Table 1, stratiﬁed by
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eGFRcr MDRD category. Participants with lower eGFRcr tended to
be older, had higher rates of hypertension and congestive heart
failure, and higher ACR, compared to those with higher eGFRcr
(Table 1). Treatment of diabetes as measured using hemoglobin A1c
was similar across eGFR categories.
Prevalence of diabetes medication use
Overall metformin use was 51% and was inversely proportional
to severity of CKD, deﬁned by eGFRcr category (Fig. 1): 63% in eGFRcr
>60 ml/min/1.73 m2, 45% in eGFRcr 45–60 ml/min/1.73 m2, 8% in
eGFRcr 30–44 ml/min/1.73 m2, and 3% in eGFRcr <30 ml/min/
1.73m2 (p < 0.001). By contrast, theprevalenceof insulinuse increased
withmore severe eGFRcr categories (from25% in thosewith eGFRcr
of >60 ml/min/1.73 m2 to 65% in those with eGFRcr of <30 ml/min/
1.73m2, p < 0.001). Overall sulfonylurea usewas 28% andwas highest
among individuals with an eGFR of 45–60 ml/min/1.73 m2.
Thiazolidinedione use was low (7% overall) and did not differ by
eGFRcr category (p = 0.82). Similar trends in prevalence of diabetes
medication use were noted when severity of kidney disease was
deﬁned by serum creatinine rather than eGFRcr (data not shown).
Predictors of metformin use
In the unadjusted model examining predictors of metformin use,
we found higher probability of metformin use associatedwith higher
eGFRcr, with a plateau observed around 70–80 ml/min/1.73 m2
(p < 0.0001, Supplemental Fig. S1). In multivariable analysis, kidney
function deﬁned by either eGFRcr or serum creatinine was the stron-
gest predictor of metformin use, independent of age, gender, race,
diabetes control, and congestive heart failure (Table 2 and Supple-
mental Table S1), though clinicians seemed to be more inﬂuenced
Table 1
Characteristics of SFVA adult veterans with diabetes, by MDRD eGFRcr category
Parameter eGFR MDRD
<30 ml/min/1.73 m2
(n = 31)
eGFR MDRD
30–44 ml/min/1.73 m2
(n = 58)
eGFR MDRD
45–60 ml/min/1.73 m2
(n = 93)
eGFR MDRD
>60 ml/min/1.73 m2
(n = 368)
P-value
Male 30 (97%) 55 (95%) 87 (94%) 350 (95%) 0.89
Age (y) 69 (65–78) 78 (70–84) 75 (66–82) 66 (61–74) <0.0001
20–39 0 0 0 2 (1%)
40–59 3 (10%) 1 (2%) 9 (10%) 76 (21%)
60–79 22 (71%) 34 (59%) 55 (59%) 245 (67%)
≥80 6 (19%) 23 (40%) 29 (31%) 45 (12%)
Race/ethnicity 0.06
African-American 11 (35%) 8 (14%) 19 (20%) 81 (22%)
Asian/Paciﬁc Islander 4 (13%) 7 (12%) 15 (16%) 37 (10%)
White 7 (23%) 31 (53%) 39 (42%) 171 (46%)
Unknown 9 (29%) 12 (21%) 20 (22%) 79 (21%)
Hypertension 30 (97%) 53 (91%) 82 (88%) 283 (77%) 0.0009
Hemoglobin A1c 7.1 (5.9–8.4) 7.2 (6.5–8.1) 7.0 (6.3–7.5) 6.9 (6.2–7.9) 0.42
<7% (<53 mmol/mol) 14 (45%) 23 (40%) 46 (49%) 198 (54%)
7–7.9% (53–63 mmol/mol) 7 (23%) 19 (33%) 31 (33%) 81 (22%)
8–8.9% (64–74 mmol/mol) 6 (19%) 6 (10%) 7 (8%) 40 (11%)
≥9% (>75 mmol/mol) 4 (13%) 10 (17%) 9 (10%) 49 (13%)
BMI (kg/m2) 31 (25–34) 29 (26–33) 28 (25–32) 31 (27–35) 0.02
Hyperlipidemia 22 (71%) 40 (69%) 66 (71%) 260 (71%) 0.99
Cardiovascular disease 8 (26%) 9 (16%) 13 (14%) 52 (14%) 0.37
Congestive heart failure 9 (29%) 22 (38%) 15 (16%) 26 (7%) <0.0001
Creatinine (mg/dL) 3.34 (2.68–6.96) 1.88 (1.70–2.06) 1.43 (1.32–1.53) 0.96 (0.85–1.10) <0.0001
eGFR MDRD 22 (9–26) 38 (33–41) 54 (50–57) 86 (73–100) <0.0001
eGFRcr CKD Epi 2012 19 (9–23) 34 (29–37) 50 (45–52) 82 (69–94) <0.0001
eGFRcys 20 (9–24) 31 (25–37) 46 (36–53) 73 (56–92) <0.0001
ACR (mg/g) 759 (110–1616) 61 (20–319) 36 (10–149) 11 (5–40) <0.0001
Abbreviations: eGFR = estimated glomerular ﬁltration rate; MDRD = Modiﬁed Diet in Renal Disease; BMI = body mass index.
Continuous outcomes are summarized by median (interquartile range).
Figure 1. Diabetes medication use by adult Veterans in San Francisco, by eGFR category.
3D.S. Tuot et al. / Journal of Clinical & Translational Endocrinology 3 (2016) 1–6
to withhold metformin due to eGFRcr than serum creatinine. In the
fully adjustedmodel, compared to individuals with anMDRD eGFRcr
of >60 ml/min/1.37 m2, the likelihood of metformin use was 23%
lower for persons with eGFRcr of 45–59 ml/min/1.73 m2 and 82%
lower among individuals with an MDRD eGFRcr of 30–44 ml/min/
1.73m2. In a comparable, multivariable adjusted model using serum
creatinine, compared to individuals with a serum creatinine of
<1.2 mg/dL, the likelihood of metformin use was 51% lower among
individuals with a serum creatinine of 1.5 to < 1.8 mg/dL. Among
those with a creatinine of 1.2–1.5mg/dL, the likelihood of metformin
use was 22% lower, although the association did not reach statis-
tical signiﬁcance (p = 0.23). Individuals with better controlled
diabetes, deﬁned by a glycosylated hemoglobin <7.0% (5.3 mmol/
mol), and those with congestive heart failure were also less likely
to be prescribed metformin, independent of other factors. Younger
age appeared strongly associated with metformin use in unad-
justed analysis, though results were attenuated and not statistically
signiﬁcant after adjustment for eGFR categories. Similar results were
noted when analyses were performed using the CKD-EPI equation
to calculate eGFRcr, but with a stronger age effect (Supplemental
Table S2).
Reclassiﬁcation of metformin eligibility by eGFRcys vs. eGFRcr
Using MDRD eGFRcr categories, 84% (95%CI, 81.0–87.0, n = 461)
of individuals were eligible to use metformin as ﬁrst line therapy,
whereas 10.6% (95%CI, 8.0–13.1, n = 58) were eligible to use
metformin with caution, and 5.6% (95%CI, 3.7–7.6, n = 31) were not
eligible to use metformin. Relative to eGFRcr, eGFRcys reclassiﬁed
109 (20% of 550) patients into different eGFR categories, including
32 (5.8% of 500) patients reclassiﬁed downward into “do not use”
and 70 (12.7% of 550) reclassiﬁed downward into “use with caution”
(Table 3). The weighted kappa coeﬃcient was 0.57 suggesting mod-
erate agreement between eGFRcr and eGFRcys, while Bowker’s test
of symmetry was rejected (p < 0.001), suggesting a signiﬁcant dif-
ference in classiﬁcation. Only 7 (1.3% of 550) patients were classiﬁed
upward into a less severe eGFR category. The percentages of pa-
tients who were reclassiﬁed by eGFRcys to <30 ml/min/1.73 m2
rose from 1% (number needed to screen [NNS] = 100) among those
with eGFRcr of >60 ml/min/1.73 m2, to 9% (NNS = 11) in the eGFRcr
45–60 ml/min/1.73 m2 group, and 40% (NNS = 3) in the eGFRcr 30–
45 ml/min/1.73 m2 group.
Qualitatively similar results were noted when analyses were per-
formed using the CKD-EPI equation to calculate eGFRcr, though fewer
individuals were reclassiﬁed downward to an eGFRcys of <30 ml/
min/1.73 m2 or eGFRcys of 30–45 ml/min/1.73 m2 (Supplemental
Table S3). The percentage of patients reclassiﬁed to an eGFR of
<30 ml/min/1.73 m2 was 5% (NNS = 20) among those in the CKD-
EPI eGFRcr 45–60 ml/min/1.37 m2 group and 27% (NNS = 4) in the
eGFR 30–45 ml/min/1.73 m2 group.
Factors associated with change in category
Factors independently associated with a more severe eGFR
category by eGFRcys vs. MDRD eGFRcr were risk factors for kidney
disease: older age (aRR = 2.21 per decade, 95%CI 1.79–2.73),
ACR > 30 mg/g (aRR = 1.81, 95%CI 1.20–2.73) and higher BMI
(aRR = 1.04 per kg/m2, 95%CI 1.01–1.08) (Table 4). We did not iden-
tify any factors that had statistically signiﬁcant associations with
Table 2
Factors associated with metformin use among SFVA adult veterans with diabetes
using MDRD (n = 550)
Parameter Unadjusted Adjusted
Relative risk (95%CI) Relative risk (95%CI)
eGFRcr <30 vs. >60 0.05 (0.01, 0.38) 0.06 (0.01, 0.43)
eGFRcr 30–44 vs. >60 0.15 (0.07, 0.34) 0.18 (0.08, 0.41)
eGFRcr 45–60 vs. >60 0.71 (0.55, 0.93) 0.77 (0.59, 0.99)
Age (per decade) 0.83 (0.77, 0.90) 0.93 (0.86, 1.01)
Female vs. male 1.29 (0.96, 1.72) 1.11 (0.83, 1.49)
African-American vs.
Caucasian
0.90 (0.72, 1.13) 0.94 (0.77, 1.14)
Asian/other vs. Caucasian 1.19 (0.95, 1.51) 1.27 (1.04, 1.56)
Hypertension 0.87 (0.72, 1.05)
Hyperlipidemia 1.12 (0.92, 1.35)
BMI (per kg/m2) 1.00 (0.99, 1.01)
A1c <7% (5.3 mmol/mol)
vs. ≥7% (≥5.3 mmol/mol)
0.85 (0.72, 1.00) 0.81 (0.69, 0.94)
ACR > 30 mg/g 0.74 (0.61, 0.90)
Cardiovascular disease 0.82 (0.63, 1.07)
Congestive heart failure 0.40 (0.26, 0.63) 0.58 (0.39, 0.87)
Insulin use 0.79 (0.65, 0.97)
Abbreviations: MDRD = Modiﬁed diet in renal disease; BMI = body mass index.
Table 3
Reclassiﬁcation of eGFR categories from creatinine to cystatin C and impact on metformin eligibility using a threshold of 30 ml/min/1.73 m2
rcRFGercRFGercRFGercRFGesycRFGe
<30 ml/min/1.73 m2 30–44 ml/min/1.73 m2 45–60 ml/min/1.73 m2 >60 ml/min/1.73 m2
”eniltsrﬁ“eniltsrﬁ“”noituac“”esutonod“
(n = n()13 = n()85 = n()39 = 368)
<30 “do not use” 28 (90%) )%1(1)%9(8)%04(32
30–44 “caution” 3 (10%) 31 (53%) )%9(23)%14(83
45–60 “ﬁrst line” 0 4 (7%) )%12(67)%83(53
> )%07(952)%31(2100”eniltsrﬁ“06
Dark shading represents downward reclassiﬁed into “do not use” category; medium shading represents downward reclassiﬁcation into “use with caution” category; light
shading represents upward reclassiﬁcation.
Table 4
Factors associated with discrepancya in eGFR categoryb, among adult Veterans with
diabetes (n = 550)
Parameter eGFRcys vs. eGFR MDRD category
eGFRcys less severe vs. eGFRcys more severe vs.
Same category Same category
Odds ratio (95%CI) Odds ratio (95%CI)
n = 19 n = 178
Age (per decade) 1.36 (0.76, 2.44) 2.21 (1.79, 2.73)
Female vs. male 2.77 (0.38, 20.40) 1.15 (0.44, 2.96)
African-American vs.
Caucasian
0.32 (0.06, 1.71) 0.93 (0.54, 1.60)
Asian/other vs. Caucasian 0.40 (0.06, 2.71) 0.93 (0.48, 1.82)
BMI (per kg/m2) 0.98 (0.88, 1.08) 1.04 (1.01, 1.08)
Urinary ACR > 30 mg/g 1.88 (0.56, 6.26) 1.81 (1.20, 2.73)
Abbreviations: ACR = albumin-to-creatinine ratio.
a Discrepancy between eGFRcys and eGFRcr is deﬁned as cases where the eGFRcys
category is more or less severe than eGFRcr category, and the two eGFR values differ
by at least 5 points.
b eGFR categories are: <30, 30–45, 45–60, >60.
Bold values depict statistically signiﬁcant associations.
4 D.S. Tuot et al. / Journal of Clinical & Translational Endocrinology 3 (2016) 1–6
a less severe eGFR category by eGFRcys vs. MDRD eGFRcr. Results
were similar when using CKD-EPI to calculate eGFRcr (Supplemen-
tal Table S4), although cardiovascular disease was a signiﬁcant risk
factor and albuminuria was not.
Discussion
The beneﬁts of metformin for treatment of diabetes mellitus have
long been appreciated. Since 1998, it has been considered the ﬁrst-
line agent for treatment of diabetes for individuals with preserved
renal function. Newer statements released by diabetes and nephrol-
ogy societies suggest using metformin as a ﬁrst-line agent among
individuals with mild kidney disease as well, deﬁned by an eGFR
of ≥45ml/min/1.73 m2. However, a black box warning recommend-
ing against metformin use among individuals with CKD deﬁned by
a serum creatinine threshold still exists in the United States [7,24].
Given these somewhat contrasting recommendations, we found that
the strongest predictor of metformin avoidance in one adult Vet-
erans Administration medical practice was severity of kidney
function, deﬁned by either serum creatinine or eGFRcr. Older age,
lower glycosylated hemoglobin and congestive heart failure were
also associated with decreasedmetformin use, but to a lesser extent.
Because a variety of factors may confound eGFRcr and contribute
to metformin’s underuse, we tested the effect of eGFRcys on eGFR
classiﬁcation and metformin eligibility. Surprisingly, we found that
eGFRcys more frequently moved patients into worse eGFR catego-
ries, resulting in decreased metformin eligibility.
The risk and beneﬁt tradeoffs of metformin use among pa-
tients with diabetes and CKD support the use of a second measure
of kidney function to improve eGFR classiﬁcation and safemetformin
use. On the one hand, diabetic adults with CKD may particularly
beneﬁt from metformin relative to other oral diabetes agents, as
recent studies have suggested a lower risk of stroke, hospitaliza-
tion for acute myocardial infarction, eGFR decline or development
of ESRD, and death, among individuals who initiate diabetes therapy
with metformin compared to a sulfonylurea [2,3]. Additionally,
metformin is associated with fewer hypoglycemic events com-
pared to other oral diabetes agents [25]. CKD independently
predisposes to hypoglycemia via decreased gluconeogenesis and
abnormal insulin metabolism [26]. This is also an important con-
sideration for older adults with diabetes, as hospital admission rates
for hypoglycemia in this population, often associated with falls [27],
now exceed those for hyperglycemia [28]. On the other hand, risk
of lactic acidosis among patients using metformin with severely im-
paired kidney function is real, though relatively rare [6].
Cystatin C has been recommended as a conﬁrmatory test to di-
agnose CKD among individuals in whom creatinine-based eGFR
measurements may not be accurate [16,28]. Compared to creatinine-
based estimates of kidney function, cystatin C-based estimates are
more highly correlated with eGFR decline among patients with di-
abetes [29]. Cystatin C may thus be useful to identify individuals
at higher risk of metformin accumulation and lactic acidosis, po-
tentially leading to safer prescribing practices. In our study, cystatin
C reclassiﬁed 21% of individuals into different clinical eGFR catego-
ries compared to MDRD eGFRcr. Most patients were reclassiﬁed
downward into a more severe eGFR categories. The number of pa-
tients needed to screen with cystatin C to reclassify an individual
to <30 ml/min/1.73 m2 (not eligible for metformin) was 11 among
those with an MDRD eGFRcr of 45–60 ml/min/1.73 m2 and approx-
imately 3 among those with MDRD eGFRcr of 30–45 ml/min/
1.73 m2. While the overall degree of reclassiﬁcation by cystatin C
was consistent with prior studies, its predominantly uni-directional
nature, with many more patients reclassiﬁed into a more severe
eGFRcys category compared to eGFRcr, was surprising [30]. This
ﬁnding may be driven by the lower muscle mass among patients
with diabetes, which is not accounted for in either the MDRD or
the CKD-EPI GFR estimating equations but is independent of eGFRcys
[15]. The insensitivity of eGFRcr may be of most clinical impor-
tance among older patients, those who are obese, have albuminuria,
or have an eGFRcr of <60 ml/min/1.73 m2, as these were indepen-
dent predictors of more severe cystatin C-based eGFR clinical
categories in our study.
The ideal method to estimate kidney function remains an area
of active research, as all kidney function estimation formulas have
shortcomings when compared to the gold standard of measured GFR
using urinary or plasma clearance of exogenous ﬁltration markers
[31]. Given its cost, imprecision, and measurement challenges, the
role of measured GFR in clinical practice is also uncertain. Our study
protocol, which compared cystatin C and serum creatinine-based
estimates of GFR in a consecutive sample of adult Veterans with di-
abetes in primary care, mirrored a clinical setting. The strategy of
ordering a conﬁrmatory cystatin C for safe and enhanced prescrib-
ing of metformin is highly applicable to a variety of clinical settings.
We did not compare creatinine-based estimates of GFR with esti-
mates based on the combined creatinine–cystatin equation, as we
were unaware of clinical laboratories that are reporting eGFR using
the combined equation. However, because the combined equation
approximates the average of eGFRcr and eGFRcys, it may be the ideal,
single estimating equation for clinical use. This was a single center
study with Veterans who were primarily older and male. Results
cannot necessarily be extrapolated to other populations, although
our study population was ethnically diverse and cystatin C has been
shown to reclassify eGFR categories across diverse research patient
populations [30].
In conclusion, we conﬁrm low metformin use among individu-
als with mild kidney disease. Educational campaigns that highlight
the recent recommendations formetformin eligibilitymay be helpful
to enhance its use among individuals with preserved kidney func-
tion, while a clinical trial is needed to determine the risks and
beneﬁts of metformin use among individuals with eGFR of 30–
44 ml/min/1.73 m2. Given the degree of reclassiﬁcation of clinical
eGFR categories with cystatin C compared to creatinine, particu-
larly for older diabetic adults with obesity, albuminuria, and/or eGFR
of <60 ml/min/1.73 m2, a strategy of reﬂexively measuring cystatin
C in these populations before prescription (and possibly yearly) may
also be helpful for clinicians. A second eGFR measurement with
cystatin C may lead to less metformin use among individuals with
an eGFRcr of <45 ml/min/1.73 m2 due to downward reclassiﬁca-
tion. But, conﬁrmation of eGFR of ≥45ml/min/1.73m2 with cystatin
C may result in greater clinician conﬁdence to use metformin for
this more sizeable population. A prospective study examining the
risks/beneﬁts of such a strategy on clinician prescribing practices
and patient-level adverse events is needed to elucidate the role of
cystatin C for metformin prescribing purposes.
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